For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Silent rhinovirus infection was associated with increased Th2 inflammation levels in the control group and reduced Th2 inflammation levels in the CRSwNP group. Silent rhinovirus (RV) infection is ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

Patients cited many benefits of multidisciplinary CRSwNP care, including personalized treatment and more therapeutic options. “Patients with [chronic rhinosinusitis with nasal polyps (CRSwNP)] may be ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

On March 11, 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially declared a pandemic. More than 7 million people have since died from COVID.

Immune cells called natural killer cells can target and eliminate tumours. The gene expression and spatial distribution of the immune cells in the tumour microenvironment indicates whether liver ...

The management framework of CRSwNP substantially shifted with the introduction of biological agents. 1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic ...